New Jersey Assembly Bill A612

New Jersey 2026-2027 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

Requires health insurers, SHBP, and SEHBP to provide coverage for certain drug regimens for treatment of AIDS or HIV under certain circumstances.

Impact

The legislation aims to enhance accessibility to crucial healthcare treatments for individuals living with HIV/AIDS. By mandating coverage for effective treatment regimens, it seeks to ensure that patients can obtain necessary medications without undue delay. Insurers that implement a prior authorization process must complete it within 14 days, setting a standard timeframe that can significantly impact patients' access to timely care. The bill also aims to align state health benefits with contemporary clinical practices and recommendations, thereby improving health outcomes for affected populations.

Summary

Assembly Bill A612 requires health insurers in New Jersey to provide coverage for prescribed combination antiretroviral drug treatments necessary for the treatment of AIDS or HIV. This coverage must be offered under specific circumstances where a single tablet drug regimen is effective or in cases when a multi-tablet regimen is equally effective and endorsed by medical professionals experienced in treating these diseases. The bill emphasizes adherence to clinically-driven guidelines and highlights the need for timely responses from insurers when assessing medical necessity through prior authorization processes.

Contention

While the bill has the potential to improve treatment access, it may also face scrutiny from health insurers regarding the feasibility and financial implications of expanded coverage. Proponents argue that the bill is essential for public health and combating the transmission of HIV/AIDS, whereas opponents may raise concerns about the increased burden on insurance providers. Additionally, the effectiveness of the prior authorization timelines and their impact on health outcomes could be subjects of debate, as delays in authorization could still affect patient well-being.